This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ASM journals Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barbhaiya, R H Articles by Hak, L J Search for Related Content PubMed PubMed Citation Articles by Barbhaiya, R H Articles by Hak, L J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 July; 36(7): 1387-1391

Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

R H Barbhaiya, C A Knupp, M Pfeffer, D Zaccardelli, G M Dukes, W Mattern, K A Pittman and L J Hak

Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Syracuse, New York 13221-4755.

ABSTRACT

The pharmacokinetics of cefepime were studied in 10 male patients receiving continuous ambulatory peritoneal dialysis therapy. Five patients received a single 1,000-mg dose and the other five received a single 2,000-mg dose; all doses were given as 30-min intravenous infusions. Serial plasma, urine, and peritoneal dialysate samples were collected; and the concentrations of cefepime in these fluids were measured over 72 h by using a high-performance liquid chromatographic assay with UV detection. Pharmacokinetic parameters were calculated by noncompartmental methods. The peak concentrations in plasma and the areas under the plasma concentration-versus-time curve for the 2,000-mg dose group were twice as high as those observed for the 1,000-mg dose group. The elimination half-life of cefepime was about 18 h and was independent of the dose. The steady-state volume of distribution was about 22 liters, and values for the 1,000- and 2,000-mg doses were not significantly different. The values for total body clearance and peritoneal dialysis clearance were about 15 and 4 ml/min, respectively. No dose dependency was observed for the clearance estimates. Over the 72-h sampling period, about 26% of the dose was excreted intact into the peritoneal dialysis fluid. For 48 h postdose, mean concentrations of cefepime in dialysate at the end of each dialysis interval exceeded the reported MICs for 90% of the isolates (MIC90s) for bacteria which commonly cause peritonitis resulting from continuous peritoneal dialysis. A parenteral dose of 1,000 or 2,000 mg of cefepime every 48 h would maintain the antibiotic levels in plasma and peritoneal fluid above the MIC90s for the most susceptible bacteria for the treatment of systemic and intraperitoneal infections [corrected].

---

Antimicrob Agents Chemother. 1992 July; 36(7): 1387-1391

This article has been cited by other articles:

• Ibrahim, R. B, Liu, C. Y, Cronin, S. M, Murphy, B. C, Cha, R., Swerdlow, P., Avila, T., Smith, S. T, Lewis, R. A, Edwards, D. J (2009). Influence of plasma exchange on the disposition of the fourth generation cephalosporin cefepime. J Oncol Pharm Pract 15: 217-222 [Abstract]  
• Malone, R. S., Fish, D. N., Abraham, E., Teitelbaum, I. (2001). Pharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 45: 3148-3155 [Abstract] [Full Text]